- Remove All
- Your shopping cart is currently empty
Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $213 | In Stock | |
5 mg | $553 | In Stock | |
10 mg | $868 | In Stock | |
25 mg | $1,280 | In Stock | |
50 mg | $1,730 | In Stock |
Description | Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma. |
In vivo | Methods: Ivuxolimab (10 mg/kg, intravenous injection, twice a week for 3 weeks) was used to treat mice bearing a CT26 tumor model, and its effect on tumors in mice was observed. Results: Ivuxolimab significantly inhibited tumor growth in the CT26 tumor model without causing significant weight loss. [1] |
Cas No. | 2128729-41-7 |
Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.